Introducing the Sleek Sleepaxa Mosaic Dark Black FL-41 Tinted Migraine Glasses: Ultimate Relief and Style Combined
*If You have chosen Prescription Lens Please upload the Prescription Below.
*Note: Prescription glasses are usually delivered within 7-9 working days.
File upload failed. Please try again.

Sleepaxa Trust
🔬 Spectrometer Lab Reports
All Sleepaxa lenses are tested using TM-3+ Spectrometer against ISO 12312-1, ANSI Z80.3, and AS/NZS 1067.1 standards.
| Parameter | Value | Status |
|---|---|---|
| Visible Light Transmittance | 50.47% | - |
| Blue Light Blocking (380-500nm) | 99.87% | PASS |
| 480nm Melanopsin Peak | 0.05% | 99.95% BLOCKED |
| UV400 Protection | 0.67% max | PASS |
| UV-B (280-315nm) | 0.01% | PASS |
| UV-A (315-380nm) | 0.08% | PASS |
| Parameter | Value | Status |
|---|---|---|
| Visible Light Transmittance | 41.10% | - |
| FL-41 Band Filtration (480-520nm) | ~12-13% | FILTERED |
| Red Light Transmission (620-700nm) | 87-100% | HIGH |
| UV400 Protection | 0.73% max | PASS |
| UV-B (280-315nm) | 0.00% | PASS |
| UV-A (315-380nm) | 0.08% | PASS |
🎓 Sleepaxa Proprietary Research
Sleepaxa is the only Indian eyewear company with peer-reviewed published research on photobiological lens design.
Wavelength-Selective Filtration in Photobiological Eyewear
Dubey S, Choudhary M (2026) | Zenodo Technical Report | 46+ Views | 37+ Downloads
ipRGC Subtypes, Signalling Pathways & Implications for Eyewear Design
Dubey S, Choudhary M (2026) | Zenodo Technical Report | 22 Peer-Reviewed References
📜 Sleepaxa Patent Portfolio
NeuroCalm FLX+™
Indian Patent IN 202521094370 | All 10 Claims Approved
Dual-band selective light attenuation technology. Simultaneously filters 460-490nm (melanopsin/ipRGC pain pathway) and 585-600nm (cone-driven pain pathway) while preserving the beneficial 520-560nm green band. Addresses both migraine pain mechanisms identified by Harvard research (Noseda et al., 2016). India's first granted patent in photobiological eyewear.
Circadian560™
Indian Patent Application IN 202521120977
Peak-blocking circadian protection technology. Achieves 100% attenuation of blue light at the melanopsin activation peak, with comprehensive blocking extending to the 560nm upper boundary of the melanopsin sensitivity envelope. Engineered for maximum melatonin protection during evening screen use, based on the published action spectrum (Brainard et al., 2001, Journal of Neuroscience).
Total IP Portfolio: 4 Patents (1 Granted + 3 Pending) | DPIIT Recognised Startup
✅ Company Credentials
| Company | Sleepaxa Private Limited |
| Founded | 2023 | Mumbai, Maharashtra, India |
| Recognition | DPIIT Recognised Startup | CTRI Registered |
Suraj Dubey
Senior Optometrist, Researcher & Innovator
Founder & Head of R&D, Sleepaxa Private Limited. Inventor of NeuroCalm FLX+™ and Circadian560™. Named inventor on 4 Indian patents. Published researcher with peer-reviewed technical reports on photobiological lens design.
ORCID: 0009-0003-7510-9254
Dr. Monica Choudhary
Director MCVI | Ex-AIIMS Professor | Renowned Author & Optometrist
Founding Member, Clinical Advisory Board, Sleepaxa Private Limited. Former faculty at the All India Institute of Medical Sciences (AIIMS), New Delhi. Brings institutional-grade clinical oversight and academic rigour to all Sleepaxa lens technologies and published research.
| Patents | 4 Patents (1 Granted + 3 Pending) |
| Published Research | 2 Technical Reports with DOI (Zenodo + Academia.edu) |
| Wikidata Entity | Q138837663 |
| Crunchbase | Heat Score: 91 |
- Sku: SA-MO-DB-MIG-ZP
- Available: instock
- Vendor: SleepAxa
- Collections: FL-41 Migraine Relief Glasses , New Arrival , Trending Collection







